Women's Health Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Others), By Application (Female Infertility, Post enopausal Osteoporosis, Endometriosis, Contraception, Others), By Region & Competition, 2021-2031F
The Global Women?s Health Market is projected to expand from USD 16.76 Billion in 2025 to USD 25.49 Billion by 2031, registering a CAGR of 7.24%. This sector comprises a wide array of pharmaceuticals, medical devices, and diagnostics designed for conditions specifically affecting women, including gynecological cancers, reproductive health issues, and autoimmune diseases. Growth is primarily driven by an aging female demographic and the rising burden of chronic pathologies, which require ongoing clinical management. For instance, the American Cancer Society estimated 310,720 new invasive breast cancer cases in the U.S. in 2024, highlighting the essential, non-discretionary demand for medical solutions that underpins market stability.
Despite these positive indicators, the market faces significant hurdles due to historical funding gaps and complex regulatory environments. Research into female-specific biology has often received less capital than other therapeutic areas, creating an innovation bottleneck. This inequitable resource allocation, compounded by high clinical trial costs, hinders the commercialization of new treatments. Consequently, financial and regulatory challenges threaten to slow the rollout of essential healthcare solutions, thereby limiting the market's ability to fully address the diverse needs of the global patient population.
Market Driver
The surge in FemTech and digital health innovations acts as a major catalyst for market growth, transforming the delivery of reproductive and general care. By integrating artificial intelligence and mobile connectivity, this sector offers personalized solutions for fertility management, menstruation tracking, and menopause support, bridging access gaps and reducing dependence on traditional clinics. In July 2024, Flo Health secured a $200 million Series C investment led by General Atlantic to boost its predictive capabilities, a move that validates the commercial viability of direct-to-consumer tools and highlights technological scalability as a core element of the healthcare infrastructure.
Government policies and increased funding for women?s healthcare research further stabilize and accelerate the industry. State-sponsored initiatives are actively addressing historic underfunding by de-risking early-stage research in neglected areas such as maternal health and endometriosis. For example, the Advanced Research Projects Agency for Health (ARPA-H) committed $100 million in February 2024 to fund novel female health research, enabling high-risk, high-reward projects. The World Economic Forum noted in 2024 that closing the gender health gap could add $1 trillion annually to the global economy by 2040, providing strong economic motivation for systemic investment.
Market Challenge
Historical funding disparities severely restrict the women's health market by limiting the capital available for research and development. This lack of equitable financial allocation creates an innovation bottleneck, complicating the efforts of pharmaceutical and medical device companies to push novel treatments through expensive clinical trials. As a result, the development of therapies tailored to female biology encounters significant delays, which restricts the availability of effective management strategies for chronic pathologies.
The consequences of this underinvestment are highlighted by the disproportionately small share of global research funding assigned to this sector. According to the World Economic Forum in 2024, only 1 percent of total healthcare R&D investment was allocated to female-specific conditions outside of oncology. This minimal financial commitment hampers the market's ability to diversify its portfolio and address unmet medical needs. Consequently, the sector struggles to reach its full commercial potential, leaving a large portion of the global patient population without adequate therapeutic options.
Market Trends
The proliferation of at-home diagnostic testing for reproductive and hormonal health is reshaping the landscape by decentralizing care and overcoming barriers to clinical access. Driven by a demand for privacy and convenience, this trend allows patients to conduct critical screenings for conditions like cervical cancer and sexually transmitted infections at home. Self-collection methods notably improve compliance among under-screened groups who may avoid traditional pelvic exams. In April 2025, Labcorp introduced a nationwide FDA-approved solution for self-collected vaginal HPV testing, targeting populations not up to date with recommended screenings.
Simultaneously, the development and commercialization of non-hormonal contraceptive innovations are becoming a critical force, addressing patient preferences for family planning without hormonal side effects. This trend focuses on long-acting reversible contraceptives (LARCs) that use advanced materials to ensure efficacy without systemic hormonal intervention. These innovations provide necessary alternatives for women contraindicated for or dissatisfied with hormonal options. In January 2025, Sebela Pharmaceuticals announced that their hormone-free Copper 175mm2 IUD achieved a Pearl Index of 0.94 in a Phase 3 study, validating the effectiveness of these novel solutions.
Key Market Players
In this report, the Global Women's Health Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Women's Health Market.
Available Customizations:
Global Women's Health Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Despite these positive indicators, the market faces significant hurdles due to historical funding gaps and complex regulatory environments. Research into female-specific biology has often received less capital than other therapeutic areas, creating an innovation bottleneck. This inequitable resource allocation, compounded by high clinical trial costs, hinders the commercialization of new treatments. Consequently, financial and regulatory challenges threaten to slow the rollout of essential healthcare solutions, thereby limiting the market's ability to fully address the diverse needs of the global patient population.
Market Driver
The surge in FemTech and digital health innovations acts as a major catalyst for market growth, transforming the delivery of reproductive and general care. By integrating artificial intelligence and mobile connectivity, this sector offers personalized solutions for fertility management, menstruation tracking, and menopause support, bridging access gaps and reducing dependence on traditional clinics. In July 2024, Flo Health secured a $200 million Series C investment led by General Atlantic to boost its predictive capabilities, a move that validates the commercial viability of direct-to-consumer tools and highlights technological scalability as a core element of the healthcare infrastructure.
Government policies and increased funding for women?s healthcare research further stabilize and accelerate the industry. State-sponsored initiatives are actively addressing historic underfunding by de-risking early-stage research in neglected areas such as maternal health and endometriosis. For example, the Advanced Research Projects Agency for Health (ARPA-H) committed $100 million in February 2024 to fund novel female health research, enabling high-risk, high-reward projects. The World Economic Forum noted in 2024 that closing the gender health gap could add $1 trillion annually to the global economy by 2040, providing strong economic motivation for systemic investment.
Market Challenge
Historical funding disparities severely restrict the women's health market by limiting the capital available for research and development. This lack of equitable financial allocation creates an innovation bottleneck, complicating the efforts of pharmaceutical and medical device companies to push novel treatments through expensive clinical trials. As a result, the development of therapies tailored to female biology encounters significant delays, which restricts the availability of effective management strategies for chronic pathologies.
The consequences of this underinvestment are highlighted by the disproportionately small share of global research funding assigned to this sector. According to the World Economic Forum in 2024, only 1 percent of total healthcare R&D investment was allocated to female-specific conditions outside of oncology. This minimal financial commitment hampers the market's ability to diversify its portfolio and address unmet medical needs. Consequently, the sector struggles to reach its full commercial potential, leaving a large portion of the global patient population without adequate therapeutic options.
Market Trends
The proliferation of at-home diagnostic testing for reproductive and hormonal health is reshaping the landscape by decentralizing care and overcoming barriers to clinical access. Driven by a demand for privacy and convenience, this trend allows patients to conduct critical screenings for conditions like cervical cancer and sexually transmitted infections at home. Self-collection methods notably improve compliance among under-screened groups who may avoid traditional pelvic exams. In April 2025, Labcorp introduced a nationwide FDA-approved solution for self-collected vaginal HPV testing, targeting populations not up to date with recommended screenings.
Simultaneously, the development and commercialization of non-hormonal contraceptive innovations are becoming a critical force, addressing patient preferences for family planning without hormonal side effects. This trend focuses on long-acting reversible contraceptives (LARCs) that use advanced materials to ensure efficacy without systemic hormonal intervention. These innovations provide necessary alternatives for women contraindicated for or dissatisfied with hormonal options. In January 2025, Sebela Pharmaceuticals announced that their hormone-free Copper 175mm2 IUD achieved a Pearl Index of 0.94 in a Phase 3 study, validating the effectiveness of these novel solutions.
Key Market Players
- AbbVie, Inc
- Bayer AG
- Merck & Co., Inc
- Pfizer, Inc
- Teva Pharmaceutical Industries Ltd
- Amgen, Inc
- Apothecus Pharmaceutical Corp
- Blairex Laboratories, Inc
- Ferring B.V.
- Agile Therapeutics
In this report, the Global Women's Health Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Women's Health Market, By Drugs
- Prolia
- Xgeva
- Evista
- Mirena
- Zometa
- Others
- Women's Health Market, By Application
- Female Infertility
- Post enopausal Osteoporosis
- Endometriosis
- Contraception
- Others
- Women's Health Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Women's Health Market.
Available Customizations:
Global Women's Health Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL WOMEN'S HEALTH MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Others)
5.2.2. By Application (Female Infertility, Post enopausal Osteoporosis, Endometriosis, Contraception, Others)
5.2.3. By Region
5.2.4. By Company (2025)
5.3. Market Map
6. NORTH AMERICA WOMEN'S HEALTH MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drugs
6.2.2. By Application
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Women's Health Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drugs
6.3.1.2.2. By Application
6.3.2. Canada Women's Health Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drugs
6.3.2.2.2. By Application
6.3.3. Mexico Women's Health Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drugs
6.3.3.2.2. By Application
7. EUROPE WOMEN'S HEALTH MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drugs
7.2.2. By Application
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Women's Health Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drugs
7.3.1.2.2. By Application
7.3.2. France Women's Health Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drugs
7.3.2.2.2. By Application
7.3.3. United Kingdom Women's Health Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drugs
7.3.3.2.2. By Application
7.3.4. Italy Women's Health Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drugs
7.3.4.2.2. By Application
7.3.5. Spain Women's Health Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drugs
7.3.5.2.2. By Application
8. ASIA PACIFIC WOMEN'S HEALTH MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drugs
8.2.2. By Application
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Women's Health Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drugs
8.3.1.2.2. By Application
8.3.2. India Women's Health Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drugs
8.3.2.2.2. By Application
8.3.3. Japan Women's Health Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drugs
8.3.3.2.2. By Application
8.3.4. South Korea Women's Health Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drugs
8.3.4.2.2. By Application
8.3.5. Australia Women's Health Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drugs
8.3.5.2.2. By Application
9. MIDDLE EAST & AFRICA WOMEN'S HEALTH MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drugs
9.2.2. By Application
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Women's Health Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drugs
9.3.1.2.2. By Application
9.3.2. UAE Women's Health Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drugs
9.3.2.2.2. By Application
9.3.3. South Africa Women's Health Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drugs
9.3.3.2.2. By Application
10. SOUTH AMERICA WOMEN'S HEALTH MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drugs
10.2.2. By Application
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Women's Health Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drugs
10.3.1.2.2. By Application
10.3.2. Colombia Women's Health Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drugs
10.3.2.2.2. By Application
10.3.3. Argentina Women's Health Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drugs
10.3.3.2.2. By Application
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL WOMEN'S HEALTH MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. AbbVie, Inc
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Bayer AG
15.3. Merck & Co., Inc
15.4. Pfizer, Inc
15.5. Teva Pharmaceutical Industries Ltd
15.6. Amgen, Inc
15.7. Apothecus Pharmaceutical Corp
15.8. Blairex Laboratories, Inc
15.9. Ferring B.V.
15.10. Agile Therapeutics
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL WOMEN'S HEALTH MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Others)
5.2.2. By Application (Female Infertility, Post enopausal Osteoporosis, Endometriosis, Contraception, Others)
5.2.3. By Region
5.2.4. By Company (2025)
5.3. Market Map
6. NORTH AMERICA WOMEN'S HEALTH MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drugs
6.2.2. By Application
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Women's Health Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drugs
6.3.1.2.2. By Application
6.3.2. Canada Women's Health Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drugs
6.3.2.2.2. By Application
6.3.3. Mexico Women's Health Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drugs
6.3.3.2.2. By Application
7. EUROPE WOMEN'S HEALTH MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drugs
7.2.2. By Application
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Women's Health Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drugs
7.3.1.2.2. By Application
7.3.2. France Women's Health Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drugs
7.3.2.2.2. By Application
7.3.3. United Kingdom Women's Health Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drugs
7.3.3.2.2. By Application
7.3.4. Italy Women's Health Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drugs
7.3.4.2.2. By Application
7.3.5. Spain Women's Health Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drugs
7.3.5.2.2. By Application
8. ASIA PACIFIC WOMEN'S HEALTH MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drugs
8.2.2. By Application
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Women's Health Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drugs
8.3.1.2.2. By Application
8.3.2. India Women's Health Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drugs
8.3.2.2.2. By Application
8.3.3. Japan Women's Health Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drugs
8.3.3.2.2. By Application
8.3.4. South Korea Women's Health Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drugs
8.3.4.2.2. By Application
8.3.5. Australia Women's Health Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drugs
8.3.5.2.2. By Application
9. MIDDLE EAST & AFRICA WOMEN'S HEALTH MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drugs
9.2.2. By Application
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Women's Health Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drugs
9.3.1.2.2. By Application
9.3.2. UAE Women's Health Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drugs
9.3.2.2.2. By Application
9.3.3. South Africa Women's Health Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drugs
9.3.3.2.2. By Application
10. SOUTH AMERICA WOMEN'S HEALTH MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drugs
10.2.2. By Application
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Women's Health Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drugs
10.3.1.2.2. By Application
10.3.2. Colombia Women's Health Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drugs
10.3.2.2.2. By Application
10.3.3. Argentina Women's Health Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drugs
10.3.3.2.2. By Application
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL WOMEN'S HEALTH MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. AbbVie, Inc
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Bayer AG
15.3. Merck & Co., Inc
15.4. Pfizer, Inc
15.5. Teva Pharmaceutical Industries Ltd
15.6. Amgen, Inc
15.7. Apothecus Pharmaceutical Corp
15.8. Blairex Laboratories, Inc
15.9. Ferring B.V.
15.10. Agile Therapeutics
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
